GlassScriptPhysician profile
Stacy Lynn Shinn
NPI 1932826971
$2,870.38
in general payments reported to CMS, 2019-2025
25 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,451 · 2024: $1,300 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,429 · Education: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,428.55 |
| Education | $441.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $312.85 | 2023-2024 | Opdivo, Opdualag, Krazati |
| Genzyme Corporation | $269.70 | 2023-2024 | |
| Abbvie INC. | $230.90 | 2023-2025 | |
| Incyte Corporation | $230.34 | 2023-2024 | Jakafi |
| Sanofi-Aventis U.S. LLC | $197.99 | 2023-2024 | |
| Lilly USA, LLC | $168.18 | 2023-2025 | Jaypirca, Verzenio, Mounjaro |
| Gilead Sciences, INC. | $159.40 | 2023-2024 | Trodelvy |
| Jazz Pharmaceuticals INC. | $150.49 | 2024 | |
| Pharmacosmos Therapeutics INC. | $147.89 | 2023 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $141.10 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $103.06 | 2024 | Givlaari |
| Karyopharm Therapeutics INC. | $95.34 | 2023 | Xpovio |
| Puma Biotechnology, INC. | $93.68 | 2023 | Nerlynx |
| Janssen Biotech, INC. | $89.92 | 2023-2024 | Darzalex, Balversa, Akeega |
| Eisai INC. | $87.10 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $72.64 | 2023 | Cabometyx |
| Celgene Corporation | $69.70 | 2023-2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $61.56 | 2024 | Keytruda |
| Genentech USA, INC. | $56.43 | 2024 | Tecentriq, Alecensa, Columvi |
| Bayer Healthcare Pharmaceuticals INC. | $29.89 | 2024 | |
| Stemline Therapeutics INC. | $24.20 | 2023 | Orserdu |
| Agios Pharmaceuticals, INC. | $23.72 | 2024 | |
| Novartis Pharmaceuticals Corporation | $21.71 | 2023 | |
| Novocure INC. | $17.51 | 2023 | Optune |
| Pfizer INC. | $15.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Shinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.